VK2735 for Weight Management Phase 3
← catalyst calendarNCT07104500 · readout in 316 d
Sponsored by Viking Therapeutics, Inc. (industry) · VKTX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
4,500estimated
Sites
137
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-23 | actual | When the study began enrolling |
| Primary completion | 2027-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Weight Loss
Intervention
- Drug: VK2735
Primary outcome
what the primary-completion date above is the date OFPercentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment
measured 78 Weeks
Permalink · VKTX's whole pipeline · Catalyst calendar · Every registered study · What changed